[The course of coronary heart disease and quality of life in patients with anxiety of different degree].
Ibatov Ad
Abstract
Ibatov Ad
Abstract
AIM: To study an emotional status and quality of life (QL) in patients with coronary heart disease (CHD) and anxiety, to evaluate efficacy of anxiolytic drug lorazepam (lorafen) in such patients. MATERIAL AND METHODS: Anxiety in 277 CHD patients was assessed by hospital scale of anxiety and depression, depression--by Beck's questionnaire, QL--by Seattle questionnaire. RESULTS: CHD patients with clinically significant anxiety had more serious vegetative disorders, worse QL and prognosis. Lorazepam treatment improved both emotional state of the patients and QL. CONCLUSION: High prevalence of anxious disorders in CHD patients deteriorating QL and prognosis dictates the necessity of detecting and treating anxiety in CHD patients.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
AIM: To study an emotional status and quality of life (QL) in patients with coronary heart disease (CHD) and anxiety, to evaluate efficacy of anxiolytic drug lorazepam (lorafen) in such patients. MATERIAL AND METHODS: Anxiety in 277 CHD patients was assessed by hospital scale of anxiety and depression, depression--by Beck's questionnaire, QL--by Seattle questionnaire. RESULTS: CHD patients with clinically significant anxiety had more serious vegetative disorders, worse QL and prognosis. Lorazepam treatment improved both emotional state of the patients and QL. CONCLUSION: High prevalence of anxious disorders in CHD patients deteriorating QL and prognosis dictates the necessity of detecting and treating anxiety in CHD patients.
Key concepts: Medicine, Anxiety, Lorazepam, Depression (economics), Quality of life (healthcare), Coronary heart disease, Anxiolytic, Disease